Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 6/20 | 0.38 |
| ▸ | BCHE | P06276 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21704556 | 0.81 | CACNA1G (0.42) | CACNA1GBCHE | |
| SCHEMBL27530381 | 0.69 | FABP7 (0.43) | TSHR | |
| SCHEMBL11419619 | 0.62 | TSHR (0.50) | TSHR | |
| SCHEMBL24970481 | 0.61 | MEN1 (0.43) | TSHR | |
| SCHEMBL4653452 | 0.61 | L3MBTL1 (0.49) | — | |
| Benzene SCHEMBL3802036 | 0.60 | CYP2C19 (0.62) | TSHR | |
| SCHEMBL21704555 | 0.60 | CASP3 (0.39) | TSHR | |
| SCHEMBL21704569 | 0.60 | CASP3 (0.39) | TSHR | |
| SCHEMBL22540303 | 0.60 | TDP1 (0.61) | TSHR | |
| SCHEMBL23974127 | 0.59 | SMN1; SMN2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066413-B2 | Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2021-07-20 | — | — | US | disclosed |
| US-20200048270-A1 | AMINOPYRIMIDINE FIVE-MEMBERED HETEROCYCLIC COMPOUND, AND INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048270-A1 | AMINOPYRIMIDINE FIVE-MEMBERED HETEROCYCLIC COMPOUND, AND INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ADORA2A, ADORA2B, ADORA3 | CACNA1G 4046/4885BCHE 1486/4885TSHR 904/4885 |
| US-11066413-B2 | Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof | ADORA2A, ADORA2B, ADORA3 | CACNA1G 4046/4885BCHE 1486/4885TSHR 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.